Neoantigen specific TCR-T cell therapy - Alaunos Therapeutics
Latest Information Update: 06 Sep 2023
At a glance
- Originator ZIOPHARM Oncology
- Developer Alaunos Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 15 Aug 2023 Alaunos Therapeutics terminates a TCR-T phase I/II library trial in Solid tumours in USA to focus on its hunTR® TCR discovery platform
- 25 May 2023 Adverse events and efficacy data from a phase I/II trial in in Solid tumours released by Alaunos Therapeutics
- 28 Jan 2022 Phase-I/II clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (Parenteral) (NCT05194735)